Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Using registries to identify adverse events in rheumatic diseases.

Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.

Pediatrics. 2013 Nov;132(5):e1384-94. doi: 10.1542/peds.2013-0755. Epub 2013 Oct 21. Review.

2.

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M; American College of Rheumatology; European League Against Rheumatism.

Arthritis Rheum. 2011 Mar;63(3):573-86. doi: 10.1002/art.30129.

3.

American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M.

Ann Rheum Dis. 2011 Mar;70(3):404-13. doi: 10.1136/ard.2011.149765.

PMID:
21292833
4.

Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Tesch G, Amur S, Schousboe JT, Siegel JN, Lesko LJ, Bai JP.

AAPS J. 2010 Sep;12(3):243-53. doi: 10.1208/s12248-010-9182-4. Epub 2010 Mar 16.

5.

Antiphosphotyrosine blotting.

Siegel JN.

Curr Protoc Immunol. 2001 May;Chapter 11:Unit 11.3. doi: 10.1002/0471142735.im1103s03.

PMID:
18432704
6.

Preparation and analysis of phosphorylated proteins.

Siegel JN.

Curr Protoc Immunol. 2001 May;Chapter 11:Unit 11.2. doi: 10.1002/0471142735.im1102s03.

PMID:
18432703
7.

Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable.

Felson DT, Zhang B, Siegel JN.

Ann Rheum Dis. 2008 May;67(5):580-3. doi: 10.1136/ard.2007.079632. No abstract available.

8.

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.

Okada SK, Siegel JN.

JAMA. 2006 Nov 8;296(18):2201-2; author reply 2203-4. No abstract available.

PMID:
17090760
9.

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.

Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN.

Arthritis Rheum. 2006 May;54(5):1429-34.

10.

Tuberculosis associated with therapy against tumor necrosis factor alpha.

Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF.

Arthritis Rheum. 2005 Oct;52(10):2968-74. Review. No abstract available.

11.

Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor.

Siegel JN, Zhen BG.

Arthritis Rheum. 2005 Jun;52(6):1637-41. No abstract available.

12.

Tuberculosis cases associated with infliximab and etanercept.

Winthrop KL, Siegel JN.

Clin Infect Dis. 2004 Oct 15;39(8):1256-7. No abstract available.

PMID:
15486859
13.

Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, Braun MM.

J Rheumatol. 2004 Oct;31(10):1955-8.

PMID:
15468359
14.

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM.

Clin Infect Dis. 2004 Aug 1;39(3):295-9. Epub 2004 Jul 16.

PMID:
15306993
15.

Infectious complications of biologic treatments of rheumatoid arthritis.

Mohan AK, Coté TR, Siegel JN, Braun MM.

Curr Opin Rheumatol. 2003 May;15(3):179-84. Review.

PMID:
12707568
16.

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM.

Arthritis Rheum. 2002 Oct;46(10):2565-70.

17.

Drug-induced systemic lupus erythematosus and TNF-alpha blockers.

Mohan AK, Edwards ET, Coté TR, Siegel JN, Braun MM.

Lancet. 2002 Aug 24;360(9333):646. No abstract available.

PMID:
12241965
18.

Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture.

Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC.

Am J Pathol. 2002 Sep;161(3):867-73.

19.

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN.

Arthritis Rheum. 2001 Dec;44(12):2862-9.

20.

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM.

N Engl J Med. 2001 Oct 11;345(15):1098-104.

21.

A three-stage clinical trial design for rare disorders.

Honkanen VE, Siegel AF, Szalai JP, Berger V, Feldman BM, Siegel JN.

Stat Med. 2001 Oct 30;20(20):3009-21.

PMID:
11590629
22.

Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART.

Patterson BK, McCallister S, Schutz M, Siegel JN, Shults K, Flener Z, Landay A.

AIDS. 2001 Sep 7;15(13):1635-41.

PMID:
11546937
23.
24.

CD8+ lymphocytes in pregnancy and HIV infection: characterization of CD8+ subpopulations and CD8+ noncytotoxic antiviral activity.

Rich KC, Siegel JN, Jennings C, Rydman RJ, Landay AL.

AIDS Res Hum Retroviruses. 1999 May 1;15(7):665-70.

PMID:
10331445
25.

Hypogammaglobulinemia and anemia 18 years after thymoma resection.

Raschal S, Siegel JN, Huml J, Richmond GW.

J Allergy Clin Immunol. 1997 Dec;100(6 Pt 1):846-8.

PMID:
9438496
26.

Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals.

Blair PJ, Boise LH, Perfetto SP, Levine BL, McCrary G, Wagner KF, St Louis DC, Thompson CB, Siegel JN, June CH.

J Clin Immunol. 1997 May;17(3):234-46.

PMID:
9168404
28.

Induction of erythroid gene expression by microcell fusion.

Kanamori H, Siegel JN.

Exp Cell Res. 1997 Apr 10;232(1):90-6.

PMID:
9141625
29.

Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals.

Perfetto SP, Hickey TE, Blair PJ, Maino VC, Wagner KF, Zhou S, Mayers DL, St Louis D, June CH, Siegel JN.

Cytometry. 1997 Feb 15;30(1):1-9.

PMID:
9056736
30.

Intact antigen receptor-mediated calcium signals in patients with early stage HIV-1 infection.

Hickey TE, Blair PJ, Perfetto S, Smoot DS, Wagner KF, St Louis DC, Mayers DL, Siegel JN, June CH.

J Immunol. 1996 May 15;156(10):4012-7.

PMID:
8621943
31.

Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells.

Taylor-Fishwick DA, Siegel JN.

Eur J Immunol. 1995 Dec;25(12):3215-21.

PMID:
8566003
32.
33.

A phenotypic study of CD8+ lymphocyte subsets in infants using three-color flow cytometry.

Jennings C, Rich K, Siegel JN, Landay A.

Clin Immunol Immunopathol. 1994 Apr;71(1):8-13.

PMID:
8137561
34.

Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells.

Siegel JN, June CH, Yamada H, Rapp UR, Samelson LE.

J Immunol. 1993 Oct 15;151(8):4116-27.

PMID:
8409389
35.

Reduced susceptibility to HIV-1 infection of ethyl-methanesulfonate-treated CEM subclones correlates with a blockade in their protein kinase C signaling pathway.

Hillman K, Qian J, Siegel JN, Roderiquez G, Blackburn R, Manischewitz J, Norcross M, Golding H.

J Immunol. 1992 Jun 15;148(12):3991-8.

PMID:
1351090
36.

Reactivity of anti-human C-reactive protein (CRP) and serum amyloid P component (SAP) monoclonal antibodies with limulin and pentraxins of other species.

Ying SC, Marchalonis JJ, Gewurz AT, Siegel JN, Jiang H, Gewurz BE, Gewurz H.

Immunology. 1992 Jun;76(2):324-30.

37.

A protease-sensitive site in the proposed Ca(2+)-binding region of human serum amyloid P component and other pentraxins.

Kinoshita CM, Gewurz AT, Siegel JN, Ying SC, Hugli TE, Coe JE, Gupta RK, Huckman R, Gewurz H.

Protein Sci. 1992 Jun;1(6):700-9.

38.

Localization of sequence-determined neoepitopes and neutrophil digestion fragments of C-reactive protein utilizing monoclonal antibodies and synthetic peptides.

Ying SC, Shephard E, de Beer FC, Siegel JN, Harris D, Gewurz BE, Fridkin M, Gewurz H.

Mol Immunol. 1992 May;29(5):677-87.

PMID:
1374844
39.

Preferential binding and aggregation of rabbit C-reactive protein with arginine-rich proteins.

Dougherty TJ, Gewurz H, Siegel JN.

Mol Immunol. 1991 Oct;28(10):1113-20.

PMID:
1922103
40.

Multiple signal transduction pathways activated through the T cell receptor for antigen.

Siegel JN, Egerton M, Phillips AF, Samelson LE.

Semin Immunol. 1991 Sep;3(5):325-34. Review.

PMID:
1724737
41.
43.
44.

Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction.

June CH, Fletcher MC, Ledbetter JA, Schieven GL, Siegel JN, Phillips AF, Samelson LE.

Proc Natl Acad Sci U S A. 1990 Oct;87(19):7722-6.

45.

Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein.

Kinoshita CM, Ying SC, Hugli TE, Siegel JN, Potempa LA, Jiang H, Houghten RA, Gewurz H.

Biochemistry. 1989 Dec 12;28(25):9840-8.

PMID:
2692716
46.

Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits.

Noe DA, Murphy PA, Bell WR, Siegel JN.

Am J Physiol. 1989 Jul;257(1 Pt 2):R49-56.

PMID:
2473659
47.
48.

T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substrates.

Hsi ED, Siegel JN, Minami Y, Luong ET, Klausner RD, Samelson LE.

J Biol Chem. 1989 Jun 25;264(18):10836-42.

49.
50.

C-reactive protein in aging Lobund Wistar rats.

Siegel JN, Gewurz H.

Prog Clin Biol Res. 1989;287:127-32. No abstract available.

PMID:
2922422

Supplemental Content

Loading ...
Support Center